Mainstream

Celldex slides after barzolvolimab hits target but fails to improve eoe symptoms in phase 2 trial

Celldex slides after Barzolvolimab hits target but fails to improve EoE symptoms in phase 2 trial

Celldex slides after Barzolvolimab hits target but fails to improve EoE symptoms in phase 2 trial

Post ContentcldxRead More

You might also be interested in reading The9-backed Nanyang Biologics to go public via $1.5B SPAC merger; shares up.

August 20, 2025
In Mainstream